comparemela.com

Latest Breaking News On - Apellis pharmaceuticals daily - Page 5 : comparemela.com

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Holdings Decreased by Lisanti Capital Growth LLC

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Holdings Decreased by Lisanti Capital Growth LLC
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Cedric-francois
Adamj-townsend
Raymond-james
Fiera-capital-corp
Jennison-associates
Apellis-pharmaceuticals
Lisanti-capital-growth
News-ratings-for-apellis-pharmaceuticals-daily
Apellis-pharmaceuticals-inc
Quarter-for-apellis-pharmaceuticals
Nasdaq
Exchange-commission

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down to $48.81

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down to $48.81
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Cambridge
Cambridgeshire
United-kingdom
Pascal-deschatelets
Raymond-james
Adamj-townsend
Zurcher-kantonalbank-zurich-cantonalbank
Apellis-pharmaceuticals-stock-performance
First-horizon-advisors-inc
Cambridge-trust-co
Commonwealth-equity-services
News-ratings-for-apellis-pharmaceuticals-daily

Apellis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:APLS)

Apellis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:APLS)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

China
Timothy-eugene-sullivan
Pascal-deschatelets
Raymond-james
First-horizon-advisors-inc
Covestor-ltd
Goldman-sachs-group
Securities-exchange-commission
Apellis-pharmaceuticals
Needham-company
Nasdaq
Stephens-consulting

Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.5% After Analyst Downgrade

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares fell 3.5% during trading on Monday after Mizuho lowered their price target on the stock from $60.00 to $52.00. Mizuho currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $48.01 and last traded at $48.11. 88,800 shares changed hands during trading, […]

United-states
American
Cedric-francois
Raymond-james
Pascal-deschatelets
Apellis-pharmaceuticals-stock-down
Insider-transactions-at-apellis-pharmaceuticals
Apellis-pharmaceuticals-company-profile
Profund-advisors
Nasdaq
Apellis-pharmaceuticals
Apellis-pharmaceuticals-inc

Apellis Pharmaceuticals (NASDAQ:APLS) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a report released on Friday, Benzinga reports. The firm currently has a $92.00 target price on the stock. Other equities research analysts have also recently issued research reports about the company. UBS Group upped their target price on Apellis […]

China
Mark-jeffrey-delong
Pascal-deschatelets
Robertw-baird
China-universal-asset-management-co
Stephens-consulting
Apellis-pharmaceuticals-trading
Covestor-ltd
Nasdaq
Apellis-pharmaceuticals
Financial-wealth-managment
Jpmorgan-chase-co

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.